摘要
目的 :观察噻氯匹定对 2型糖尿病病人血小板活化状态的影响。方法 :48例 2型糖尿病病人口服噻氯匹定 2 5 0mg ,每日 1次 ,疗程 4wk。结果 :治疗后 ,病人的血小板聚集率、血小板α颗粒膜蛋白、凝血烷B2 (TXB2 )的差值分别为 (-1 1±9) % ,(-5 4± 49) μg·L-1,(-71± 65 )ng·L-1均显著下降 (P <0 .0 1 ) ;6 酮 前列腺素F1α(6 K PGF1α)上升 ,差值为 (4± 4)ng·L-1,T/K(TXB2与 6 K PGF1α的比值 )比值下降 ,差值为 -5± 4,差异有非常显著意义 (P <0 .0 1 )。结论 :噻氯匹定能有效地降低 2型糖尿病病人的血小板聚集率、改善血小板活化状态。
AIM: To observe the effects of ticlopidine on activation of platelet in type 2 diabetes mellitus. METHODS: Forty eight patients with type 2 diabetes mellitus were treated with ticlopidine in a dose of 250 mg daily for 4 wk. RESULTS: After treatment, the platelet aggregation(PAG),α granule membrane glycoprotein(GMP 140) and the thromboxane B 2 of patients markedly reduced( P < 0.01 ). The differences were(-11±9) %,(-54±49) μg·L -1 ,(-71±65) ng·L -1 , while the 6 keto prostaglandin F 1α increased. The differences were (4±4) ng·L -1 , so as to cause a significant lowering of T/K ratio( P <0.01) the differences were (-5±4),there was significant difference ( P<0.01). CONCLUSION: Ticlopidine can significantly reduce the platelet aggregation, improve activation of platelet and resume the balance of T/K of patients with type 2 diabetes mellitus.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2002年第7期422-425,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
噻氯匹定
糖尿病
非胰岛素依赖型
血小板聚集抑制剂
ticlopidine
diabetes mellitus, non insulin dependent
platelet aggregation inhibiors
